摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-溴-2-丙氧基吡啶 | 850142-79-9

中文名称
5-溴-2-丙氧基吡啶
中文别名
——
英文名称
5-bromo-2-propoxypyridine
英文别名
——
5-溴-2-丙氧基吡啶化学式
CAS
850142-79-9
化学式
C8H10BrNO
mdl
——
分子量
216.077
InChiKey
YAWVJCMWTJITGM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    235.2±20.0 °C(Predicted)
  • 密度:
    1.386±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    22.1
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090
  • 危险性防范说明:
    P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
  • 危险性描述:
    H315,H319
  • 储存条件:
    室温、密封、干燥

SDS

SDS:c9ef36b74a7c0fef3db6b093f891e771
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-Bromo-2-propoxypyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-2-propoxypyridine
CAS number: 850142-79-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H10BrNO
Molecular weight: 216.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
    摘要:
    这项发明涉及公式的新吡咯烷衍生物,涉及它们作为药物的用途,涉及它们的治疗用途的方法,以及含有它们的药物组合物。
    公开号:
    US20140213568A1
  • 作为产物:
    描述:
    5-溴-2-硝基吡啶 在 sodium hydride 作用下, 以 异丙醇 为溶剂, 反应 2.5h, 以72%的产率得到5-溴-2-丙氧基吡啶
    参考文献:
    名称:
    [EN] FUSED LACTAM COMPOUNDS
    [FR] COMPOSES DE LACTAME CONDENSE
    摘要:
    本发明提供了一种具有公式(I)的化合物,其中R1代表一个具有6到10个环碳原子的芳基团等;R2代表一个氢原子等,n代表0、1或2;所说的杂芳基团未取代或取代,所说的芳基至少被一个从由取代基a组成的组中选择的取代基t所取代;所说的取代基a是从由卤素原子、具有1到6个碳原子的烷基团等组成的组中选择的;或者该化合物的药物可接受的酯,或者其药物可接受的盐。这些化合物用于治疗由NDA NR2B受体过度激活引起的疾病状况,如疼痛、中风、创伤性脑损伤、帕金森病、阿尔茨海默病、抑郁症、焦虑症、偏头痛或类似疾病,特别是在哺乳动物中,特别是人类。本发明还提供了一种包含上述化合物的药物组合物。
    公开号:
    WO2005035523A1
点击查看最新优质反应信息

文献信息

  • Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: Study of 6-substituted pyridine-3-boronic acid derivatives
    作者:Fanny Fontaine、Arnaud Héquet、Anne-Sophie Voisin-Chiret、Alexandre Bouillon、Aurélien Lesnard、Thierry Cresteil、Claude Jolivalt、Sylvain Rault
    DOI:10.1016/j.ejmech.2015.02.056
    日期:2015.5
    including hydrophilic fluoroquinolones. Starting from 6-benzyloxypyridine-3-boronic acid I that we previously identified as a potential inhibitor of the NorA efflux pump against the NorA-overexpressing S. aureus 1199B strain (SA1199B), we describe here the synthesis and biological evaluation of a series of 6-(aryl)alkoxypyridine-3-boronic acids. 6-(3-Phenylpropoxy)pyridine-3-boronic acid 3i and 6-
    响应于抗生素的广泛使用,细菌已经进化出许多防御抗菌剂的机制。其中,通过外排泵将抗菌剂挤出细菌细胞外是引起关注的主要原因。起初仅限于一种或几种与结构相关的抗生素,然后细菌耐药性逐渐发展为不同种类抗生素之间的交叉耐药性,从而产生了多药耐药性微生物。这些病原体的出现需要开发新的治疗策略,抑制外排泵似乎是可以恢复现有抗生素效力的有前途的策略。NorA是黄色葡萄球菌研究最多的染色体外排泵; 已知这暗示了耐甲氧西林黄色葡萄球菌(MRSA)菌株对包括亲喹诺酮在内的各种无关底物的抗性。从我们先前鉴定为NorA过表达Sure aureus黄色葡萄球菌1199B菌株(SA1199B)的NorA外排泵的潜在抑制剂的6-苄氧基吡啶-3-硼酸I开​​始,我们在此描述一系列6-(芳基)烷氧基吡啶-3-硼酸。发现6-(3-苯丙氧基)吡啶-3-硼酸3i和6-(4-苯基丁氧基)吡啶-3-硼酸3j与母体化合物I
  • [EN] PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] DÉRIVÉS DE PYRROLIDINE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET UTILISATIONS ASSOCIÉES
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2014114578A1
    公开(公告)日:2014-07-31
    The invention relates to new pyrrolidine derivatives of the formula (I), to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    这项发明涉及公式(I)的新吡咯烷衍生物,其用作药物,用于其治疗用途的方法以及含有它们的药物组合物。
  • [EN] ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] DÉRIVÉS D'ÉTHYNE, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2012032014A1
    公开(公告)日:2012-03-15
    invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    这项发明涉及公式I的新化合物,涉及它们作为药物的用途,涉及它们的治疗用途的方法,以及含有它们的药物组合物。
  • New compounds, pharmaceutical compositions and uses thereof
    申请人:ROTH Gerald Juergen
    公开号:US20120214782A1
    公开(公告)日:2012-08-23
    The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    这项发明涉及公式I的新化合物,以及它们作为药物的用途,它们的治疗用途的方法,以及含有它们的药物组合物。
  • [EN] ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS<br/>[FR] COMPOSÉS DE TYPE ALCYNE EN TANT QU'INHIBITEURS DE LA S-NITROSOGLUTATHIONE RÉDUCTASE
    申请人:GLENMARK PHARMACEUTICALS SA
    公开号:WO2016055947A1
    公开(公告)日:2016-04-14
    Provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof, wherein A, B, R 1, R 2, m and n are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).
    提供的是式(Ia)的化合物及其药学上可接受的盐,其中A、B、R1、R2、m和n如本文所定义,这些化合物作为S-硝基谷胱甘肽还原酶(GSNOR)的抑制剂具有活性。这些化合物可以预防、抑制或抑制GSNOR的作用,因此在治疗GSNOR介导的疾病、疾病、综合征或病症方面具有用处,例如肺动脉高压、急性呼吸窘迫综合征(ARDS)、哮喘、支气管痉挛、咳嗽、肺炎、肺纤维化、间质性肺疾病、囊性纤维化和慢性阻塞性肺疾病(COPD)。
查看更多